Haixi New Drug: The Phase I clinical trial recruitment for the oral medication project HXP056 for wAMD has been completed, and the Phase II study has been initiated.

2026-03-28 06:10:22

Haixi New Drug Announcement, the company’s innovative drug project HXP056, is expected to become the world’s first oral medication targeting hemorrhagic retinal diseases. Patient recruitment for wet age-related macular degeneration (wAMD) in China was initiated in early July 2025. The recruitment for all patients in the single ascending dose (SAD) and multiple ascending dose (MAD) phases of the Phase I clinical trial has been completed, and after four weeks of continuous dosing, the dose-limiting toxicity (DLT) assessment and pharmacokinetic (PK) data collection have been completed. Preliminary efficacy assessments are also ongoing. In the fourth quarter of 2025, the company has initiated the dose-expansion Phase II clinical study.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes